ADHD in childhood epilepsy: Clinical determinants of severity and of the response to methylphenidate

Attention‐deficit/hyperactivity disorder (ADHD) is commonly observed in children with epilepsy. However, factors associated with the development of ADHD and which might help to guide its therapeutic management, remain an issue of debate.

[1]  E. Rook.  AB0179 Revision of European Medicine Agency's (EMA) Guideline on Clinical Investigation of Medicinal Products Other than Nsaids for Treatment of Rheumatoid Arthritis, 2016 , 2016 .

[2]  S. Rheims,et al.  Partial validation of a French version of the ADHD-rating scale IV on a French population of children with ADHD and epilepsy. Factorial structure, reliability, and responsiveness , 2016, Epilepsy & Behavior.

[3]  E. Simonsen,et al.  Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials , 2015, BMJ : British Medical Journal.

[4]  Tobias Loddenkemper,et al.  Should epileptiform discharges be treated? , 2015, Epilepsia.

[5]  A. Palmini,et al.  Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult-to-treat epilepsies , 2015, Epilepsy & Behavior.

[6]  A. Herigstad,et al.  Attention deficit/hyperactivity disorder and interictal epileptiform discharges: It is safe to use methylphenidate? , 2015, Seizure.

[7]  B. Bourgeois,et al.  Comparing stimulant effects in youth with ADHD symptoms and epilepsy , 2014, Epilepsy & Behavior.

[8]  C. Gillberg,et al.  Neurobehavioral Comorbidities in Children With Active Epilepsy: A Population-Based Study , 2014, Pediatrics.

[9]  H. Feldman,et al.  Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. , 2014, The New England journal of medicine.

[10]  R. Scott,et al.  Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: Evidence of clinical benefit , 2013, Epilepsia.

[11]  L. Booij,et al.  The impact of methylphenidate on seizure frequency and severity in children with attention‐deficit–hyperactivity disorder and difficult‐to‐treat epilepsies , 2013, Developmental medicine and child neurology.

[12]  F. Sung,et al.  Correlation between Epilepsy and Attention Deficit Hyperactivity Disorder: A Population-Based Cohort Study , 2013, PloS one.

[13]  Marco Mula,et al.  Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan , 2012, The Lancet.

[14]  K. Scheffler,et al.  Attention‐deficit/hyperactivity disorder in childhood epilepsy: A neuropsychological and functional imaging study , 2012, Epilepsia.

[15]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[16]  E. Casella,et al.  Efficacy and safety of methylphenidate in treating ADHD symptoms in children and adolescents with uncontrolled seizures: A Brazilian sample study and literature review , 2011, Epilepsy & Behavior.

[17]  J Helen Cross,et al.  Epilepsy in the WHO European region: Fostering epilepsy care in Europe , 2011, Epilepsia.

[18]  B. Bourgeois,et al.  Adaptive phase I study of OROS methylphenidate treatment of attention deficit hyperactivity disorder with epilepsy , 2010, Epilepsy & Behavior.

[19]  D. Hirtz,et al.  Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. , 2010, The New England journal of medicine.

[20]  G. Salmon,et al.  Attention deficit hyperactivity disorder. , 2018, British journal of hospital medicine.

[21]  Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder , 2010 .

[22]  C. Gillberg,et al.  Omega-3/Omega-6 Fatty Acids for Attention Deficit Hyperactivity Disorder , 2009, Journal of attention disorders.

[23]  A. Torres,et al.  Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: Review of pharmacological treatment , 2008, Epilepsy & Behavior.

[24]  V. Madaan,et al.  Assessing the Efficacy of Treatments for ADHD , 2008, CNS drugs.

[25]  A. McMillan,et al.  The frequency, complications and aetiology of ADHD in new onset paediatric epilepsy. , 2007, Brain : a journal of neurology.

[26]  E. Sherman,et al.  ADHD, Neurological Correlates and Health‐related Quality of Life in Severe Pediatric Epilepsy , 2007, Epilepsia.

[27]  D. Michelson,et al.  ADHD rating scale IV: psychometric properties from a multinational study as clinician‐administered instrument , 2005, International journal of methods in psychiatric research.

[28]  S. Faraone,et al.  Attention-deficit hyperactivity disorder , 2005, The Lancet.

[29]  M. Rappley,et al.  Clinical practice. Attention deficit-hyperactivity disorder. , 2005, The New England journal of medicine.

[30]  W. Hauser,et al.  ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. , 2004, Archives of general psychiatry.

[31]  J. Buitelaar,et al.  Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. , 2004, Journal of the American Academy of Child and Adolescent Psychiatry.

[32]  J. Newcorn.  Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder , 2003, The American journal of psychiatry.

[33]  S. West,et al.  Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study , 2002 .

[34]  J. Wernicke,et al.  Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. , 2001, Pediatrics.

[35]  D. Faries,et al.  Validation of the ADHD Rating Scale as a clirlician administered and scored instrument , 2001 .

[36]  S. Zecker,et al.  Stimulant therapy and seizure risk in children with ADHD. , 2001, Pediatric neurology.

[37]  R. Shalev,et al.  Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? , 1997, The Journal of pediatrics.

[38]  R. Mattson,et al.  Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy. , 1989, Epilepsia.